The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.
Primary care physician (PCPs): physicians such as family medicine practitioners and internists who do not specialize in neurological care.
Secondary care physicians (SCPs): physicians such as geriatricians or neurologists who see patients for specific reasons.
Tertiary care physicians (TCPs): specialty neurologists who focus on certain neurological conditions.
Group 1: PCPs who routinely evaluate and manage patients over the age of 50 in a family practice or internist setting.
In the 18 months prior to identification have prior or associated HCP-ordered referral or prior prescription of drug therapies, for the SCIC
Participants with previous amyloid- or tau-specific tests, defined as
Amyloid position emission tomography (PET)
Tau PET
Parallel
P-tau217
Diagnostic testBlood biomarker testing
Standard of Care
Other interventionStandard of care
Difference in Proportion of Participants Between the Primary Care Physician (PCP) Tested Group and the PCP Control Group with at Least 1 Management Action
Difference in proportion of participants with a least 1 management action, referral to Secondary or Tertiary Care Physician (S/TCP); counseling; Alzheimer's Disease (AD) drug therapy related to cognitive complaint, or Non-AD drug therapy related to cognitive complaint.
Difference in Proportion of Participants Between the S/TCP Tested Group and the S/TCP Control Group with at Least 1 Management Action
Difference in proportion of participants with a least 1 management action, referral to S/TCP; counseling; AD drug therapy related to cognitive complaint, or Non-AD drug therapy related to cognitive complaint.
Time from Cognitive Complaint to Date of Referral to a S/TCP Between the PCP Tested Group and the PCP Control Group:
Time from Cognitive Complaint to Date of Counseling Between the PCP Tested Group and the PCP Control Group
Time from Cognitive Complaint to Date of Initiating AD Therapy Between the PCP Tested Group and the PCP Control Group
Click on the lead sponsor to view all of their trials.
